Navigation Links
Odyssey Thera Announces U.S. Patent for Technologies Enabling Protein Interaction Screening and Directed Evolution
Date:1/5/2011

SAN RAMON, Calif., Jan. 5, 2011 /PRNewswire/ -- Odyssey Thera, Inc. announced today that the United States Patent and Trademark Office granted U.S. Patent No. 7,855,167.  The invention describes technologies and high-throughput methods for identifying bimolecular interactions in vivo based on protein-fragment complementation assays (PCA).  The patent, the eighteenth assigned to Odyssey Thera, further protects assays utilizing fragments of inherently fluorescent proteins, and the use of these assays for high-throughput screening of defined panels of proteins.  The strategy is applicable in any cell type and using a wide range of reporters and detection methods.  The invention enables identification and validation of genes and proteins involved in any cellular process, and also provides assays to study the effects drugs and gene expression or knockout on specific pathways.

"This patent significantly extends the reach of Odyssey Thera's technology platform," said John K. Westwick, Ph.D., Odyssey Thera President and CEO.  "The assays and their use in gene vs. library and library vs. library screening provide a uniquely powerful strategy for biotherapeutic identification and optimization, diagnostic and biomarker development, the discovery of genetic modifiers of animal and plant cell traits, and bioprocess engineering."

About Odyssey Thera

Odyssey Thera, Inc. is a technology company committed to developing breakthroughs in cellular analysis and engineering.  Odyssey Thera's technologies measure pathway activity within living cells, and are applicable to therapeutic discovery and development, engineering of any cell type or species, live animal imaging, and diagnostic and bioprocess applications.  To learn more about Odyssey Thera, please visit www.odysseythera.com.


'/>"/>
SOURCE Odyssey Thera, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Odyssey Thera to Participate in Expanded EPA Initiative
2. Stereotaxis Launches the Odyssey Interventional Network for Superior Online Cardiovascular Education and Training
3. Stereotaxis and Siemens Promote Integrated Odyssey(TM) Solutions
4. Odyssey Thera Announces Achievement of Pfizer Drug Candidate Milestones
5. Amicus Therapeutics to Present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011
6. DJO Incorporated Acquires Manufacturer of Compression Therapy Products, Elastic Therapy, Inc.
7. Halozyme Therapeutics to Present at J.P. Morgan Healthcare Conference on January 12
8. Karyopharm Therapeutics Inc. Appoints Michael Kauffman, MD, PhD, as Chief Executive Officer
9. Intarcia Therapeutics Executive Chairman Kurt Graves to Present at 29th Annual JP Morgan Healthcare Conference
10. Graymark Healthcares Sleep Apnea Therapy Program Services Record Number of Patients in Q4 2010
11. Medco Extends URAC Accreditation to Drug Therapy Management, PBM
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation announce a ... sensors for real-time monitoring of patients with trauma-related and ... focused on disruptive health solutions for rare disorders and ... record and integrate behavioral, cognitive, physiological and contextual data. ... ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/22/2017)... 2017  As the latest Obamacare repeal effort moves ... (R-LA) and Lindsey Graham (R-SC) medical ... device industry is in an odd place.  The industry ... excise tax on medical device sales passed along with ... patients, increased visits and hospital customers with the funding ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... cold therapy products, announced today the introduction of an innovative new design of the ... multipurpose pad so you get maximum comfort while controlling your pain while using cold ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will ... the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey ... Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), creator ... tool, and the Cancer Patient Education Network (CPEN), an independent professional organization that ... new strategic alliance. , As CPEN’s strategic partner, HLI will help support ...
Breaking Medicine News(10 mins):